Charles Schwab Investment Management Inc. Acquires 249,804 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,002,779 shares of the biopharmaceutical company’s stock after buying an additional 249,804 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.64% of Gilead Sciences worth $739,217,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Swedbank AB boosted its holdings in Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Gilead Sciences by 8.6% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 6,850 shares of the biopharmaceutical company’s stock valued at $598,000 after acquiring an additional 540 shares during the period. Harbor Capital Advisors Inc. boosted its stake in Gilead Sciences by 2.6% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 27,005 shares of the biopharmaceutical company’s stock worth $2,264,000 after acquiring an additional 695 shares during the last quarter. PDS Planning Inc grew its holdings in Gilead Sciences by 10.6% during the third quarter. PDS Planning Inc now owns 4,500 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 433 shares during the period. Finally, Moloney Securities Asset Management LLC increased its stake in Gilead Sciences by 5.4% in the third quarter. Moloney Securities Asset Management LLC now owns 25,975 shares of the biopharmaceutical company’s stock valued at $2,178,000 after purchasing an additional 1,326 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on GILD shares. Mizuho lifted their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $102.76.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 293,356 shares of company stock valued at $29,166,240 over the last 90 days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 1.1 %

Shares of Gilead Sciences stock opened at $114.74 on Wednesday. The stock has a market cap of $143.00 billion, a P/E ratio of 310.11, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $117.39. The business’s 50 day moving average is $98.28 and its 200-day moving average is $90.74.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.75%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.